Premium
Residual cardiovascular risk among people with diabetes
Author(s) -
Dash Satya,
Leiter Lawrence A.
Publication year - 2019
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13646
Subject(s) - residual risk , medicine , diabetes mellitus , disease , type 2 diabetes , atherosclerotic cardiovascular disease , cardiovascular health , environmental health , intensive care medicine , endocrinology
Type 2 diabetes (T2D) is a growing health concern across both developed and developing countries. Cardiovascular disease (CVD) remains the major cause of increased mortality in this patient population. In recent years, effective low density lipoprotein lowering treatments and other risk reduction strategies have substantially reduced the risk of atherosclerotic CVD, yet patients with T2D continue to remain at increased risk for atherosclerotic CVD. Here, we will briefly review various proposed underlying mechanisms for this residual risk with a more in‐depth focus on the potential role of triglyceride‐rich lipoproteins in residual risk and potential avenues to target this pharmacologically.